Unicycive Therapeutics posts corporate presentation on kidney disease pipeline, lead hyperphosphatemia drug OLC

• Unicycive highlighted oxylanthanum carbonate (OLC) as its lead program for hyperphosphatemia in chronic kidney disease patients on dialysis.
• NDA remains under FDA review following a complete response letter tied to third-party manufacturing deficiencies; FDA inspection of the vendor expected near term.
• Management flagged ongoing FDA discussions on label and packaging; approval expected in the near term if manufacturing issues are resolved.
• Company positioned OLC as a potential best-in-class phosphate binder, citing smaller tablets swallowed whole and lower pill burden versus existing therapies.
• Presentation reiterated cash runway into 2027 to support a potential FDA clearance and launch; U.S. hyperphosphatemia market opportunity estimated at over $1 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.